Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

Core Insights - Cardiff Oncology, Inc. has made significant progress in its clinical trials, particularly with the completion of enrollment in the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC) [2][8] - The company appointed Dr. Roger Sidhu as Chief Medical Officer to guide the development of onvansertib through the registrational phase [2][6] - Positive clinical data was announced from an investigator-initiated trial of onvansertib in combination with paclitaxel for metastatic triple negative breast cancer (mTNBC), showing a 40% objective response rate [4] Financial Overview - As of June 30, 2025, Cardiff Oncology reported cash and investments totaling approximately $71.0 million, with a projected runway into Q1 2027 [9][10] - The net cash used in operating activities for Q2 2025 was approximately $8.3 million, a decrease from $9.2 million in the same period of 2024 [9] - Total operating expenses for the quarter were approximately $14.9 million, an increase of $2.2 million from $12.7 million in Q2 2024, primarily due to costs associated with clinical trials and key hires [11] Clinical Development Highlights - The CRDF-004 trial reached its targeted enrollment across 41 clinical sites in the U.S. [8] - The Phase 1b study of onvansertib in combination with paclitaxel demonstrated a safe and manageable toxicity profile, with myelosuppression being the most common adverse event [4] - A second patent was issued for the treatment of mCRC in bevacizumab-naïve patients, with an expiration date no earlier than 2043 [5][7]